AIRISE-COV - PDX Pharmaceuticals
Alternative Names: AIRISE-COV™ - PDX PharmaceuticalsLatest Information Update: 28 Jul 2023
At a glance
- Originator PDX Pharmaceuticals
- Class Adjuvants; COVID-19 vaccines; RNA vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 27 Jun 2023 Immunogenicity data from a preclinical trial in COVID-2019 infections released by PDX Pharmaceuticals (PDX Pharmaceuticals pipeline, June 2023).
- 23 Jun 2023 PDX Pharmaceuticals has patent protection for Pdx-NPTM technology in USA(Company website - PDX Pharmaceuticals)
- 23 Jun 2023 Preclinical in COVID-2019 infections (Prevention) in USA (Parenteral)